Phase 2 portion: Unsolicited adverse events (AEs);Phase 2 portion: Solicited local and systemic adverse events (AEs);Phase 2 portion: Immediate adverse event (AEs);Phase 3 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection;Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response;Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response;Phase 2 portion: Neutralizing antibody (Nab assay) response;Phase 2 portion: Neutralizing antibody (Nab assay) response;Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths;Phase 2 portion: Percentage of subjects with normal and abnormal clinically biochemical values;Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant haematological values;Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant urine values;Phase 2 portion: Number of subjects with normal and abnormal clinically significant biochemical values;Phase 2 portion: Number of subjects with normal and abnormal clinically significant haematological values;Phase 2 portion: Number of subjects with normal and abnormal clinically significant urine values

Phase 2 portion: Unsolicited adverse events (AEs);Phase 2 portion: Solicited local and systemic adverse events (AEs);Phase 2 portion: Immediate adverse event (AEs);Phase 3 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection;Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response;Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response;Phase 2 portion: Neutralizing antibody (Nab assay) response;Phase 2 portion: Neutralizing antibody (Nab assay) response;Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths;Phase 2 portion: Percentage of subjects with normal and abnormal clinically biochemical values;Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant haematological values;Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant urine values;Phase 2 portion: Number of subjects with normal and abnormal clinically significant biochemical values;Phase 2 portion: Number of subjects with normal and abnormal clinically significant haematological values;Phase 2 portion: Number of subjects with normal and abnormal clinically significant urine values